The costs of caring: Medical costs of Alzheimer's disease and the managed care environment

Journal of Geriatric Psychiatry and Neurology

Volumn 14, Issue 4, 2001, Pages 168-178

  Murman, D L ^a  

^a B 113 Clinical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALZHEIMER DISEASE; COST CONTROL; DEMENTIA; EVIDENCE BASED MEDICINE; GERIATRIC CARE; GOVERNMENT; HEALTH CARE COST; HUMAN; LONG TERM CARE; MANAGED CARE; MEDICAID; MEDICARE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0035185837     PISSN: 08919887     EISSN: None     Source Type: Journal    
DOI: 10.1177/089198870101400402     Document Type: Review

References (93)

1. The economic burden of Alzheimer's disease care
2. The US economic and social costs of Alzheimer's disease revisited
3. Estimated prevalence of Alzheimer's disease in the United States
4. The American health care system. Health insurance coverage
5. Disease management - Promises and pitfalls
6. Alzheimer's disease care: Costs and potential savings
7. Economic research on Alzheimer disease: A review of the literature
8. Recommendations of the panel on cost-effectiveness in health and medicine
9. The effect of diagnosing Alzheimer's disease on frequency of physician visits: A case-control study
10. Hospitalization and Alzheimer's disease: Results from a community-based study
11. Cognitive impairment. Can it predict the course of hospitalized patients?
12. Cognitive impairment and hospital use
13. The incremental costs associated with behavioral symptoms in Alzheimer's disease
14. The cost of institutional care in Alzheimer's disease: Nursing home and hospital use in a prospective cohort
15. Patterns and predictors of institutionalization in community-based dementia patients
16. Longitudinal study of death and institutionalization in patients with primary degenerative dementia
17. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease
18. Descriptive analysis of emergency hospital admissions of patients with Alzheimer's disease
19. Predicting time to nursing home care and death in individuals with Alzheimer's disease
20. Predicting 10-year care requirements for older people with suspected Alzheimer's disease
21. Impact of the type and severity of dementia on hospitalization and survival of the elderly
22. The cost of dementia in Denmark: The Odense Study
23. Comparison of health care utilization and direct costs in three degenerative dementias
24. The American health care system - Medicare
25. The American health care system - Medicaid
26. Long-term care for frail elderly people - The On Lok model
27. Alzheimer's disease under managed care: Implications from Medicare utilization and expenditure patterns
28. Cost of Alzheimer's disease and related dementia in managed-medicare
29. Chronic care costs in managed care
30. How much do persons with Alzheimer's disease cost Medicare?
31. Medicare expenditures associated with Alzheimer disease
32. The economic cost of Alzheimer's disease and related dementias to the California Medicaid program ("Medi-Cal") in 1995
33. The net cost of Alzheimer disease and related dementia: A population-based study of Georgia Medicaid recipients
34. Health policy 2001: Managed care in transition
35. Managed competition and California's health care economy
36. Health policy 2001: Medicare
37. Program of All-inclusive Care for the Elderly (PACE): An innovative model of integrated geriatric care and financing
38. S/HMOs, the second generation: Building on the experience of the first social health maintenance organization demonstrations
39. Effects of the Medicare Alzheimer's disease demonstration on the use of community-based services
40. Effects of the Medicare Alzheimer's disease demonstration on Medicare expenditures
41. Effects of the Medicare Alzheimer's disease demonstration on nursing home entry
42. Effects of the Medicare Alzheimer's disease demonstration on caregiver burden and depression
43. Trends and issues in the Medicaid 1915 (c) Waiver Program
44. Paying more fairly for Medicare capitated care
45. A concerned optimist: An "exit interview" with Bruce Vladeck
46. Risk adjustment and Medicare: Taking a closer look
47. The urgent need to improve health care quality. Institute of Medicine National Roundtable on Health Care Quality
48. The American health care system - The movement for improved quality in health care
49. Does managed care lead to better or worse quality of care?
50. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality
51. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study
52. Donepezil use in managed Medicare: Effect on health care costs and utilization
53. Opportunities for improving managed care for individuals with dementia: Part 1 - The issues
54. Opportunities for improving managed care for individuals with dementia: Part 2 - A framework for care
55. Evidence-based disease management
56. Disease management
57. Documentation and evaluation of cognitive impairment in elderly primary care patients
58. Misclassification and selection bias when identifying Alzheimer's disease solely from Medicare claims records
59. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life
60. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society
61. Practice parameter: Early detection of dementia: Mild cognitive impairment
62. Practice parameter: Diagnosis of dementia
63. Improving adherence to dementia guidelines through education and opinion leaders. A randomized, controlled trial
64. Diagnosing dementia: Perspectives of primary care physicians
65. Practice parameter: Management of dementia
66. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group
67. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomized controlled trial
68. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension
69. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group
70. Diagnosis and treatment of depression in patients with Alzheimer's disease and other dementias
71. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial
72. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
73. Mental health services for Alzheimer's disease. Current trends in reimbursement and public policy, and the future under managed care
74. Psychiatric and physical morbidity effects of dementia caregiving: Prevalence, correlates, and causes
75. Caregiving as a risk factor for mortality: The Caregiver Health Effects Study
76. Psychotropic drug use among caregivers of patients with dementia
77. A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial
78. Precipitating factors for delirium in hospitalized elderly persons. Predictive model and inter-relationship with baseline vulnerability
79. Delirium: A symptom of how hospital care is failing older persons and a window to improve quality of hospital care
80. A multicomponent intervention to prevent delirium in hospitalized older patients
81. Managed care and chronic illness: Health services research needs
82. An outline for a cost-effectiveness analysis of a drug for patients with Alzheimer's disease
83. Are methods for estimating QALYs in cost-effectiveness analyses improving?
84. Analysis and interpretation of cost data in randomized controlled trials: Review of published studies
85. The economic impact of the tacrine in the treatment of Alzheimer's disease
86. An economic evaluation of donepezil in the treatment of Alzheimer's disease
87. Pharmacotherapy for people with Alzheimer's disease: A Markov-cycle evaluation of five years of therapy using donepezil
88. Cost-effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease
89. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada
90. Cost-effectiveness analysis of day care for patients with dementia disorders
91. Cost-utility analysis of group living in dementia care
92. Service use and financial performance in a replication program on adult day centers